Why the study?
Does ADAM17 inhibition prevent Angiotensin II-induced cardiovascular remodeling and hypertension in mice?
Does ADAM17 inhibition prevent Angiotensin II-induced cardiovascular remodeling and hypertension in mice?
Vascular ADAM17 mediates Angiotensin II-induced cardiovascular remodeling independent of blood pressure, highlighting it as a potential therapeutic target for hypertensive complications.
Answers are grounded in this paper and cite their sources.
ADAM17 inhibition may target AngII-driven remodeling independent of BP in mice; leaves open translation to human hypertension therapy.
Angiotensin II (AngII) has been strongly implicated in hypertension and its complications. Evidence suggests the mechanisms by which AngII elevates blood pressure and enhances cardiovascular remodeling and damage may be distinct. However, the signal transduction cascade by which AngII specifically initiates cardiovascular remodeling, such as hypertrophy and fibrosis, remains insufficiently understood. In vascular smooth muscle cells, a metalloproteinase ADAM17 mediates epidermal growth factor receptor transactivation, which may be responsible for cardiovascular remodeling but not hypertension induced by AngII. Thus, the objective of this study was to test the hypothesis that activation of vascular ADAM17 is indispensable for vascular remodeling but not for hypertension induced by AngII. Vascular ADAM17-deficient mice and control mice were infused with AngII for 2 weeks. Control mice infused with AngII showed cardiac hypertrophy, vascular medial hypertrophy, and perivascular fibrosis. These phenotypes were prevented in vascular ADAM17-deficient mice independent of blood pressure alteration. AngII infusion enhanced ADAM17 expression, epidermal growth factor receptor activation, and endoplasmic reticulum stress in the vasculature, which were diminished in ADAM17-deficient mice. Treatment with a human cross-reactive ADAM17 inhibitory antibody also prevented cardiovascular remodeling and endoplasmic reticulum stress but not hypertension in C57Bl/6 mice infused with AngII. In vitro data further supported these findings. In conclusion, vascular ADAM17 mediates AngII-induced cardiovascular remodeling via epidermal growth factor receptor activation independent of blood pressure regulation. ADAM17 seems to be a unique therapeutic target for the prevention of hypertensive complications.
No takes yet. Share an insight, caveat, or question.
Takayanagi et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: